



Press Release  
May 25, 2022

## Scandion Oncology announces change to its Board of Directors

### Thomas Feldthus will step down from the Board of Directors.

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, announces an immediate change to its Board of Directors. Thomas Feldthus, a member of the Board of Directors since 2018 and Chairman of the Audit Committee, will step down due to other professional commitments. Having recently taken the position of CEO of Saniona, Thomas Feldthus needs to free up time for this operational role.

“Thomas Feldthus has been a valued member of Scandion’s Board of Directors and while I regret his decision to step down, I also understand and respect it. I thank Thomas for his contributions during the past four years”, says Martin Møller, Chairman of the Board of Directors at Scandion.

“It has been a privilege to serve on Scandion’s Board of Directors but having recently taken on the role as CEO of Saniona, I need to free up time to fulfil my duties there. I will be looking forward to following Scandion from the outside”, says Thomas Feldthus.

A new chairman of the Audit Committee will be appointed among the existing members of the Board of Directors.

### For further information please contact:

Mads Kronborg, Head of External Communication  
Phone: +45 6051 4955  
Email: [ir@scandiononcology.com](mailto:ir@scandiononcology.com)

The information was provided by the contact person above for publication on May 25, 2022 at 17.30 CET.

**Scandion Oncology** (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.

Globally, close to 10 million patients die every year from treatment resistant cancers, and our medicines are relevant in several different cancers as oral add-on drugs to existing market leading therapies. That makes both our medical and commercial potential significant.

Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (**ticker: SCOL**).

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at [ca@vhcorp.se](mailto:ca@vhcorp.se) or +46 (0) 40 200 250.